{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-202389","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.864006+00:00","generated_at":"2026-05-14T23:57:16.141906+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cabaletta Bio reports rese-cel activity without preconditioning in 4 PV patients; ASGCT presentation May 14","bullets":["2 of 4 refractory PV patients on rese-cel at lowest dose showed compelling clinical activity through 6 months without preconditioning.","Complete peripheral B-cell elimination observed in 3 of 4 patients; 3 of 4 remained off all immunomodulators and steroids as of April 2, 2026.","Safety: 1 of 4 patients had Grade 1 CRS; no ICANS of any grade. Additional patients enrolled at higher dose in RESET-PV.","RESET-SLE trial initial dose cohort (no preconditioning) fully enrolled; initial data expected first half 2026.","Data to be presented at ASGCT 2026 Annual Meeting on May 14, 2026; higher dose durability data anticipated H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-202389","json":"https://secwatch.observer/filing/0001193125-26-202389.json","markdown":"https://secwatch.observer/filing/0001193125-26-202389.md","text":"https://secwatch.observer/filing/0001193125-26-202389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202389/0001193125-26-202389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526202389/d110169d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:57:16.141906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}